Enanta Pharmaceuticals (ENTA) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces ...

StockNews.com lowered shares of Enanta Pharmaceuticals (NASDAQ:ENTA – Free Report) from a hold rating to a sell rating in a ...

Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.05 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $1.58 per share a year ago. These ...

$ENTA insiders have traded $ENTA stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.

JMP Securities reaffirmed their market outperform rating on shares of Enanta Pharmaceuticals (NASDAQ:ENTA – Free Report) in a report released on Tuesday,Benzinga reports. JMP Securities currently has ...

In a report released yesterday, Eric Joseph from J.P. Morgan maintained a Sell rating on Enanta Pharmaceuticals (ENTA – Research Report), with ...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) insiders who purchased shares in the last 12 months were richly rewarded last week. The stock climbed by 46% resulting in a US$48m addition to the company’s ...

Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.05 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $1.58 per share a year ago.